Curis Prices $5.6M Stock-and-Warrant Offering at $1.50/Share

summarizeSummary

Curis priced a $5.6 million stock-and-warrant offering at $1.50 per share, with net proceeds of $4.8 million to fund operations into Q4 2026. The deal is highly dilutive, potentially adding over 7 million shares if all warrants are exercised.

check_boxKey Events · Financing and Capital Events · CRIS

• Offering Priced at $1.50/Share

  Curis is selling 335,001 shares of common stock at $1.50 per share, each paired with a warrant to purchase one share at $1.75, for total gross proceeds of $5.6 million.

• Pre-Funded Warrants Included

  The offering also includes 3,398,333 pre-funded warrants at $1.49 each, exercisable for $0.01 per share, allowing investors to avoid the 9.99% ownership cap.

• Net Proceeds of $4.8 Million

  After placement agent fees of $364,000 and estimated expenses of $0.4 million, Curis expects net proceeds of approximately $4.8 million to fund R&D and working capital.

• Dilution Risk

  The 335,001 shares represent about 16% of the 2.09 million shares outstanding before the offering. If all pre-funded warrants and common warrants are exercised, up to 7.13 million additional shares could be issued.

auto_awesomeAnalysis · CRIS · Life Sciences

Curis has finalized terms for a $5.6 million best-efforts offering, selling 335,001 shares at $1.50 each and 3,398,333 pre-funded warrants at $1.49 each, each paired with a five-year warrant exercisable at $1.75. Net proceeds of $4.8 million extend the company's cash runway into Q4 2026, but the offering is highly dilutive—the 335,001 shares alone represent about 16% of the 2.09 million shares outstanding before the offering, and the pre-funded warrants and common warrants could add up to 7.13 million more shares if exercised. The company remains under substantial doubt about its ability to continue as a going concern, and this capital raise is a survival move, not a growth catalyst.